Bortezomib- and dexamethasone-based regimens with or without novel anti-CD38 treatments can rapidly reduce tumor burden and improve renal function, as almost one-quarter of MM patients with severe renal impairment can even stop dialysis [36,37,38]. Here, CD38 is linked to neoplasm.